DE69943287D1 - Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen - Google Patents

Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen

Info

Publication number
DE69943287D1
DE69943287D1 DE69943287T DE69943287T DE69943287D1 DE 69943287 D1 DE69943287 D1 DE 69943287D1 DE 69943287 T DE69943287 T DE 69943287T DE 69943287 T DE69943287 T DE 69943287T DE 69943287 D1 DE69943287 D1 DE 69943287D1
Authority
DE
Germany
Prior art keywords
eyes
treatment
composition containing
antibiotic composition
containing moxifloxacin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69943287T
Other languages
German (de)
English (en)
Inventor
Gerald Cagle
Robert L Abshire
David W Stromann
John M Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69943287(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DE69943287D1 publication Critical patent/DE69943287D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69943287T 1998-09-30 1999-09-29 Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen Expired - Lifetime DE69943287D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10250698P 1998-09-30 1998-09-30
US10250498P 1998-09-30 1998-09-30

Publications (1)

Publication Number Publication Date
DE69943287D1 true DE69943287D1 (de) 2011-04-28

Family

ID=26799441

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69912972T Revoked DE69912972T2 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzungen zur behandlung des auges
DE69943287T Expired - Lifetime DE69943287D1 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69912972T Revoked DE69912972T2 (de) 1998-09-30 1999-09-29 Antibiotische zusammensetzungen zur behandlung des auges

Country Status (18)

Country Link
EP (5) EP2796138B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP2002525317A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101463243B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN100374114C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR020661A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE254458T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU762827B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI9914151B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (3) CA2342211C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1111404T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69912972T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (5) DK1117401T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (4) ES2207307T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1038691B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (5) PT1384478E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (2) TR200100883T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI222361B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000018386A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
WO2001022936A1 (en) 1999-09-24 2001-04-05 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
DE19962470A1 (de) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
WO2001089495A2 (en) * 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
CA2412575C (en) 2000-07-26 2009-12-29 Onkar N. Singh Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
JPWO2002040028A1 (ja) * 2000-11-16 2004-03-18 わかもと製薬株式会社 抗菌ゲル化点眼剤
AU2002228660A1 (en) 2000-12-20 2002-07-01 Alcon, Inc Use of amidoamines to treat or prevent acanthamoeba and fungal infections
AU2002226926A1 (en) * 2000-12-20 2002-07-01 Alcon, Inc. Antifungal compositions containing an antibiotic and one or more amidoamines
EP1429780B1 (en) 2001-09-21 2005-12-21 Alcon, Inc. Method of treating middle ear infections
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
ES2424676T3 (es) 2003-09-10 2013-10-07 Kyorin Pharmaceutical Co., Ltd. Derivado de ácido 7-(3-ciclopropilaminometil-1-pirrolidinil 4-sustituido)quinoloncarboxílico
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
AU2005282571A1 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
AU2005317228A1 (en) * 2004-12-10 2006-06-22 Alcon, Inc. Compositions for treatment of ear infections
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
TWI544934B (zh) * 2008-06-09 2016-08-11 愛爾康研究有限公司 含有氟喹諾酮抗生素藥物之經改良藥學組成物
AU2010266120B2 (en) * 2009-07-02 2014-02-06 Curofin Pharma Gmbh Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections
MX337419B (es) * 2010-01-07 2016-03-03 Univ Minnesota Metodos y composiciones para aplicar moxifloxacina al oido.
BR112014012885A2 (pt) 2011-12-06 2017-06-13 Alcon Res Ltd composição de gel celulósica com estabilidade de viscosidade aperfeiçoada
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
US9504691B2 (en) 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
CN104224802B (zh) * 2014-09-19 2017-12-12 南京优科生物医药研究有限公司 一种盐酸莫西沙星滴耳剂及其制备方法
RU2595837C2 (ru) * 2014-09-29 2016-08-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазных капель
US20180311225A1 (en) * 2015-10-29 2018-11-01 Teika Pharmaceutical Co., Ltd. External preparation
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
CA3182196A1 (en) * 2020-06-10 2021-12-16 Anthony Sampietro Compositions and uses in method for post-operative ocular care
CN116270662A (zh) * 2021-12-03 2023-06-23 苏州欧康维视生物科技有限公司 盐酸莫西沙星地塞米松磷酸钠滴眼液
KR102656260B1 (ko) 2022-10-14 2024-04-09 주식회사태준제약 목시플록사신을 포함하는 안과용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
AU4201189A (en) * 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH03109236A (ja) * 1989-09-22 1991-05-09 Hoya Corp 半導体超微粒子分散ガラスの製造方法
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
TW209865B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-01-10 1993-07-21 Bayer Ag
JP3337218B2 (ja) 1992-05-06 2002-10-21 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるホウ酸塩−ポリオール複合体の使用
DE4424369A1 (de) * 1994-07-11 1996-01-18 Bayer Ag Pyrido[3,2,1.i,j][3,1]benzoxazinderivate
JPH0892241A (ja) * 1994-09-22 1996-04-09 Ss Pharmaceut Co Ltd ５−ヒドラジノキノロンカルボン酸誘導体及びこれを有効成分とする抗菌剤
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ATE214931T1 (de) * 1995-06-06 2002-04-15 Bayer Ag Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen
JP3290914B2 (ja) * 1997-03-17 2002-06-10 参天製薬株式会社 眼組織におけるキノロン系抗菌剤の定量装置
CN1895233A (zh) * 1997-09-25 2007-01-17 拜尔公司 控释活性化合物的药物制剂
AU742428B2 (en) 1998-09-23 2002-01-03 Unilever Plc Oral care compositions
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof

Also Published As

Publication number Publication date
ES2602956T3 (es) 2017-02-23
JP5563041B2 (ja) 2014-07-30
JP2014144982A (ja) 2014-08-14
PT1384478E (pt) 2011-05-12
AU762827B2 (en) 2003-07-03
BRPI9914151B1 (pt) 2017-10-03
JP2013018799A (ja) 2013-01-31
TR200100883T2 (tr) 2001-10-22
ATE254458T1 (de) 2003-12-15
DE69912972T2 (de) 2004-04-22
WO2000018386A2 (en) 2000-04-06
CY1115916T1 (el) 2017-01-25
EP1384478B1 (en) 2011-03-16
CY1111404T1 (el) 2015-08-05
EP2796138B1 (en) 2016-08-17
JP2012067141A (ja) 2012-04-05
PT1117401E (pt) 2004-03-31
DK2269602T3 (en) 2014-12-15
CA2342211A1 (en) 2000-04-06
EP1384478A1 (en) 2004-01-28
AU1310100A (en) 2000-04-17
KR20010075138A (ko) 2001-08-09
CA2774207A1 (en) 2000-04-06
DK1117401T3 (da) 2004-02-23
AR020661A1 (es) 2002-05-22
HK1150769A1 (en) 2012-01-13
CN100374114C (zh) 2008-03-12
BRPI9914151B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-05-25
ES2526521T3 (es) 2015-01-13
JP2002525317A (ja) 2002-08-13
KR101463243B1 (ko) 2014-12-17
DK2301541T3 (da) 2014-09-01
CN1650863A (zh) 2005-08-10
EP2796138A1 (en) 2014-10-29
ES2519190T3 (es) 2014-11-06
CN1320035A (zh) 2001-10-31
AR081393A2 (es) 2012-08-29
EP2301541A1 (en) 2011-03-30
PT2269602E (pt) 2014-12-29
EP1117401B1 (en) 2003-11-19
WO2000018386A3 (en) 2000-06-08
ES2207307T3 (es) 2004-05-16
HK1059572A1 (en) 2004-07-09
JP2009007375A (ja) 2009-01-15
CA2342211C (en) 2009-05-26
BR9914151A (pt) 2001-06-26
PT2796138T (pt) 2016-09-22
ATE501732T1 (de) 2011-04-15
EP2301541B1 (en) 2014-08-20
EP2269602A1 (en) 2011-01-05
DK2796138T3 (en) 2016-12-05
TR200704370T2 (tr) 2007-11-21
CY1115759T1 (el) 2017-01-25
EP1117401A2 (en) 2001-07-25
PT2301541E (pt) 2014-10-29
TWI222361B (en) 2004-10-21
CA2659064A1 (en) 2000-04-06
HK1150756A1 (en) 2012-01-13
HK1038691A1 (en) 2002-03-28
DK1384478T3 (da) 2011-05-23
EP2269602B1 (en) 2014-11-19
DE69912972D1 (de) 2003-12-24
CN1184968C (zh) 2005-01-19
HK1038691B (en) 2004-04-23

Similar Documents

Publication Publication Date Title
DE69943287D1 (de) Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
ATE494884T1 (de) Oxidative zusammensetzung zur behandlung von keratinfasern, die spezielle aminosilikone enthält
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
DE69612465D1 (de) Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen
DE69613386D1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
HUP9900927A3 (en) Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
NO994258L (no) Anvendelse av levobupivakain for behandling av ansiktsmigrene
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
ATE350061T1 (de) Zusammensetzung zur behandlung von virusinfektionen, die einen calcium-kanal-blocker und ein chinolin enthält
DE3880953D1 (de) Chinolinderivate, verfahren zur herstellung davon und diese enthaltendes antibakterielles mittel.